Last kr101.50 SEK
Change Today +2.40 / 2.42%
Volume 3.0M
MEDAA On Other Exchanges
Symbol
Exchange
OTC US
Stockholm
Berlin
OTC US
As of 11:30 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

meda ab-a shs (MEDAA) Snapshot

Open
kr99.35
Previous Close
kr99.10
Day High
kr101.50
Day Low
kr99.35
52 Week High
04/25/14 - kr129.90
52 Week Low
11/7/13 - kr69.70
Market Cap
30.7B
Average Volume 10 Days
794.0K
EPS TTM
kr2.99
Shares Outstanding
302.2M
EX-Date
05/8/14
P/E TM
33.9x
Dividend
kr2.50
Dividend Yield
2.46%
Current Stock Chart for MEDA AB-A SHS (MEDAA)

Related News

No related news articles were found.

meda ab-a shs (MEDAA) Related Businessweek News

No Related Businessweek News Found

meda ab-a shs (MEDAA) Details

Meda AB operates as a specialty pharmaceutical company worldwide. It manufactures and sells specialty pharmaceutical products, branded generics, over-the-counter drugs, and other products in various therapy areas, such as respiratory, dermatology, gastroenterology, cardiology, pain and inflammation, and CNS, as well as metabolism/vitamins. The company markets and sells its products through distributors in approximately 120 countries. Meda AB is headquartered in Solna, Sweden.

2,925 Employees
Last Reported Date: 04/2/14

meda ab-a shs (MEDAA) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: kr2.1M
Compensation as of Fiscal Year 2013.

meda ab-a shs (MEDAA) Key Developments

Meda AB Reports Consolidated Earnings Results for the Second Quarter and Six Months and Parent Earnings Results for the Six Months Ended June 30, 2014; Provides Earnings Guidance for the Full Year 2014

Meda AB reported consolidated earnings results for the second quarter and consolidated parent earnings results for six months ended June 30, 2014. The group's net sales reached SEK 3,477 million against SEK 3,279 million, corresponding to an increase of 6% or an organic growth of 4% compared to the previous year. EBITDA was SEK 993 million against SEK 922 million, yielding a 28.6% margin (28.1) a year ago. Operating profit totaled SEK 426 million against SEK 381 million a year ago. Profit after tax amounted to SEK 243 million SEK 192 million a year ago. Earnings per share reached SEK 0.80 against SEK 0.64 a year ago. Profit attributable to parent company shareholders was SEK 243 million against SEK 194 million a year ago. The group's net sales reached SEK 6,842 million against SEK 6,478 million, corresponding to an increase of 6% or an organic growth of 4% compared to the previous year. EBITDA amounted to SEK 2,003 million against SEK 1,845 million, corresponding to a 29.3% margin (28.5) a year ago. Operating profit totaled SEK 888 million against SEK 765 million a year ago. Profit after tax amounted to SEK 503 million against SEK 400 million a year ago. Earnings per share reached SEK 1.66 against SEK 1.34 a year ago. Cash earnings per share amounted to SEK 4.14 against SEK 3.81 a year ago. Cash flow from operating activities amounted to SEK 1,297 million against SEK 1,201 million a year ago. Net debt for the group totaled SEK 15,234 million on June 30, 2014. Net debt was affected negatively in the second quarter by the dividend of SEK 756 million. Profit attributable to parent company shareholders was SEK 502 million against SEK 405 million a year ago. Return on equity was 6.0% against 6.3% a year ago. On parent company basis, net sales were SEK 2,889 million against SEK 2,639 million a year ago. Operating profit (EBIT) was SEK 449 million against SEK 237 million a year ago. Profit for the period after net financial items (EBT) was SEK 437 million against SEK 290 million a year ago. Net profit was SEK 30 million against net loss of SEK 70 million a year ago. The company expects sales for full-year 2014 of around SEK 15 billion, and the EBITDA margin to be in line with last year (excluding integration costs and other costs associated with the transaction). This corresponds to an expected organic growth for Meda standalone of 2%-3% in 2014.

Meda AB, Rottapharm S.p.A. - M&A Call

To discuss the acquisition of Rottapharm¦Madaus by Meda

Meda AB, Q2 2014 Earnings Call, Aug 13, 2014

Meda AB, Q2 2014 Earnings Call, Aug 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MEDAA:SS kr101.50 SEK +2.40

MEDAA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.111.50 CHF +1.90
Almirall SA €11.42 EUR -0.10
Ipsen SA €39.81 EUR +1.19
Orion OYJ €30.00 EUR +0.84
Recordati SpA €12.82 EUR -0.21
View Industry Companies
 

Industry Analysis

MEDAA

Industry Average

Valuation MEDAA Industry Range
Price/Earnings 31.2x
Price/Sales 2.1x
Price/Book 1.8x
Price/Cash Flow 31.2x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDA AB-A SHS, please visit www.meda.se. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.